Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Overall Study	STARTED	Levetiracetam	122
Overall Study	STARTED	Carbamazepine	121
Overall Study	STARTED	Lamotrigine	118
Overall Study	Safety Population	Levetiracetam	122
Overall Study	Safety Population	Carbamazepine	121
Overall Study	Safety Population	Lamotrigine	117
Overall Study	ITT Population	Levetiracetam	122
Overall Study	ITT Population	Carbamazepine	120
Overall Study	ITT Population	Lamotrigine	117
Overall Study	Maintenance Phase (Week 7-58)	Levetiracetam	93
Overall Study	Maintenance Phase (Week 7-58)	Carbamazepine	89
Overall Study	Maintenance Phase (Week 7-58)	Lamotrigine	93
Overall Study	COMPLETED	Levetiracetam	75
Overall Study	COMPLETED	Carbamazepine	55
Overall Study	COMPLETED	Lamotrigine	65
Overall Study	NOT COMPLETED	Levetiracetam	47
Overall Study	NOT COMPLETED	Carbamazepine	66
Overall Study	NOT COMPLETED	Lamotrigine	53

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00438451/flow